Filter news by category :
01 Mar 2023 | [Ga-68]EMP-100, Collaborations
A case of a 56-year-old female former smoker with stage IV EGFR mutation-positive NSCLC (lymphogenic, pulmonary, hepatic, and cerebral metastases is presented. Stage: cT3, cN3, cM1b) and concomitant MET exon 14 skipping mutation. After multiple pretreatments including radiochemotherapy and...
11 Apr 2022 | Collaborations, EMI-137
Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify...
06 Dec 2021 | [Ga-68]EMP-100, Collaborations
This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC. Conclusion: Visualization of c-MET expression with 68Ga-EMP-100 PET imaging...
21 May 2021 | Collaborations, EMI-137
This pilot study suggest that c-MET is a promising target for fluorescence-guided tumour identification, with the potential to improve margin assessment in pSCC. The c-MET targeted approach proved to be compatible with lymphatic mapping performed in the same patient using multicolor fluorescence...
02 Oct 2020 | EMI-137
The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No clinicallysignificant differences were observed among the cohorts, althougha...
17 Dec 2019 | Press Releases
To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a...
08 Nov 2018 | Press Releases
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom - 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately....
29 Oct 2018 | Press Releases
EDINBURGH, Scotland, October 29, 2018 - Roy Davis appointed as Non-Executive Chairman - Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the...
21 Mar 2018 | Collaborations
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s second biggest cancer killer....
20 Sep 2017 | EMI-137
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK – 19 September 2017: Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase...